Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Capital Expenditures (2019 - 2025)

aTYR PHARMA's Capital Expenditures history spans 7 years, with the latest figure at $31000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 24.0% year-over-year to $31000.0; the TTM value through Dec 2025 reached $77000.0, up 18.46%, while the annual FY2025 figure was $77000.0, 18.46% up from the prior year.
  • Capital Expenditures reached $31000.0 in Q4 2025 per ATYR's latest filing, down from $37000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.4 million in Q2 2023 to a low of $8000.0 in Q2 2024.
  • Average Capital Expenditures over 5 years is $325789.5, with a median of $37000.0 recorded in 2025.
  • Peak YoY movement for Capital Expenditures: soared 6116.67% in 2022, then plummeted 99.67% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $18000.0 in 2021, then skyrocketed by 6116.67% to $1.1 million in 2022, then crashed by 98.48% to $17000.0 in 2023, then surged by 47.06% to $25000.0 in 2024, then rose by 24.0% to $31000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Capital Expenditures are $31000.0 (Q4 2025), $37000.0 (Q3 2025), and $9000.0 (Q2 2025).